Life Sciences Commercialisation in Finland: Overview

Thomson Reuters Practical Law Life Sciences Global Guide 2023

Posted on

11 Jul

2023

Dittmar & Indrenius > Insight > Life Sciences Commercialisation in Finland: Overview

Written by

Charlotta Bonsdorff

Senior Associate

Juli Mansnérus

Partner
+358 44 272 4727
Linkedin

Inari Paila

Senior Attorney
+358 50 388 9591
Linkedin

Emilia Rosenblad

Associate
+358 40 082 6562
Linkedin

Service areas

Related

The Finnish Competition and Consumer Authority Calls for a Call-In Power – AgainThe Finnish Competition and Consumer Authority (“FCCA”) has frequently expressed it...
Mapping and Analyzing Use Cases for AIAs with all work, prioritising AI-related tasks is essential to ensure you focus your time wher...
Reform of the Act on the Secondary Use of Social and Health DataThe Act on the Secondary Use of Social and Health Data (552/2019) is being reformed The Act on...

More by the same author

Reform of the Act on the Secondary Use of Social and Health Data

The Act on the Secondary Use of Social and Health Data (552/2019) is being reformed The Act on the Secondary Use of Social and Health Data (552/2019) (the “Secondary Use Act”), which lays out rules on the use of social and health data in Finland for secondary purposes, entered into force in May 2019. Secondary use of social and health data refers to the use of such data for statistics, scientific research, development and innovation, education, policy-making and regulatory activities by public authorities.

New Legislation on Environmental Marketing: Sustainable Businesses Benefit from Ban on Greenwashing

New EU legislation on green claims will bring opportunities to sustainable businesses, although ensuring compliance with the new rules will require preparatory efforts from companies. As stricter and more detailed rules will apply to environmental claims and marketing, to prevent so-called greenwashing, companies with a genuinely sustainable product range will benefit from the new framework. Prohibition of greenwashing brings advantages to both consumers and businesses – and naturally to the environment.

The EU’s Pharmaceutical Legislation Reform

The European Union’s imminent pharmaceutical legislation reform aims to modernise its regulatory framework, focusing on improving patient access to medicines, fostering innovation, and minimising environmental impact. This strategic overhaul, set against a backdrop of industry challenges and evolving IP rights, underscores the EU’s commitment to balancing innovation with accessibility and sustainability in healthcare.

Latest insights

Draft Government Decree on Offshore Wind Power in the Finnish EEZ published for comments

Article / 25 Jun 2025

Liability for sanctions violations is increasing in Finland

Article / 20 May 2025